European Liver Patients’ Association – ELPA shared a post on LinkedIn:
“At MOSAIC, we proved it once again: when patients, scientists, and global leaders stand together – we are unstoppable.
ELPA × EASL united at MOSAIC with ELPA President Marko Korenjak, Prof. Alexander Krag, Prof. Sven Francque, and our incredible partners from the Europe, USE, France, German …and beyond — building one strong, aligned voice for people living with MASH/MASLD.
Why this matters:
MASH is not “just a liver disease” — it affects the heart, metabolism, kidneys, and increases cancer risk. With 1 in 4 adults affected worldwide, the world needs a European AND global movement that transforms science, policy, and access to care.
This is MOSAIC.
A powerhouse of multi-stakeholder, multi-specialty expertise – where patients, clinicians, regulators, and industry shape the future of clinical trials and patient-centred innovation.
Together:
- ELPA
- EASL
- Global Liver Institute
- Fatty Liver Foundation
- Fatty Liver Alliance
- AASLD
- FDA
… and more world-leading partners – we ensure liver patients are not only heard, but driving the agenda.
One global liver community. One mission. One future.
We are here to accelerate knowledge, empower patients, and make early diagnosis, clinical trial access, and effective treatments a reality for all.
Europe + Global = Impact.
When we speak with one voice, change becomes unstoppable.”
More posts featuring ELPA on OncoDaily.
